KR20240161664A - 멜팔란 플루페나미드와 시클로덱스트린을 포함하는 제형 - Google Patents

멜팔란 플루페나미드와 시클로덱스트린을 포함하는 제형 Download PDF

Info

Publication number
KR20240161664A
KR20240161664A KR1020247034012A KR20247034012A KR20240161664A KR 20240161664 A KR20240161664 A KR 20240161664A KR 1020247034012 A KR1020247034012 A KR 1020247034012A KR 20247034012 A KR20247034012 A KR 20247034012A KR 20240161664 A KR20240161664 A KR 20240161664A
Authority
KR
South Korea
Prior art keywords
melphalan flufenamide
cyclodextrin
γcd
pharmaceutically acceptable
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247034012A
Other languages
English (en)
Korean (ko)
Inventor
프레드릭 레만
피터 테오도로빅
크리스틴 해머
룬 링곰
Original Assignee
온코펩타이드즈 이노베이션 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코펩타이드즈 이노베이션 아베 filed Critical 온코펩타이드즈 이노베이션 아베
Publication of KR20240161664A publication Critical patent/KR20240161664A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247034012A 2022-03-24 2023-03-24 멜팔란 플루페나미드와 시클로덱스트린을 포함하는 제형 Pending KR20240161664A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2204171.9 2022-03-24
GBGB2204171.9A GB202204171D0 (en) 2022-03-24 2022-03-24 Novel formulations
PCT/EP2023/057729 WO2023180565A1 (en) 2022-03-24 2023-03-24 Formulations comprising melphalan flufenamide and cyclodextrin

Publications (1)

Publication Number Publication Date
KR20240161664A true KR20240161664A (ko) 2024-11-12

Family

ID=81449463

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034012A Pending KR20240161664A (ko) 2022-03-24 2023-03-24 멜팔란 플루페나미드와 시클로덱스트린을 포함하는 제형

Country Status (11)

Country Link
US (1) US20250205155A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499049A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510725A (cg-RX-API-DMAC7.html)
KR (1) KR20240161664A (cg-RX-API-DMAC7.html)
CN (1) CN119053323A (cg-RX-API-DMAC7.html)
AU (1) AU2023241241A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245985A1 (cg-RX-API-DMAC7.html)
GB (1) GB202204171D0 (cg-RX-API-DMAC7.html)
IL (1) IL315551A (cg-RX-API-DMAC7.html)
MX (1) MX2024011654A (cg-RX-API-DMAC7.html)
WO (1) WO2023180565A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025233915A1 (en) * 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
SI3228319T1 (sl) * 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
JP6284945B2 (ja) 2012-10-26 2018-02-28 オンコペプティデス エービーOncopeptides AB メルファランフルフェナミドの凍結乾燥製剤
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
WO2020079165A1 (en) 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations

Also Published As

Publication number Publication date
IL315551A (en) 2024-11-01
WO2023180565A1 (en) 2023-09-28
AU2023241241A1 (en) 2024-10-31
CA3245985A1 (en) 2023-09-28
JP2025510725A (ja) 2025-04-15
CN119053323A (zh) 2024-11-29
GB202204171D0 (en) 2022-05-11
EP4499049A1 (en) 2025-02-05
US20250205155A1 (en) 2025-06-26
MX2024011654A (es) 2025-01-09

Similar Documents

Publication Publication Date Title
KR100941210B1 (ko) 백금 유도체를 포함하는 제약 제제
JP6257734B2 (ja) デシタビン誘導体製剤
JP6106228B2 (ja) 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液
TW201039865A (en) Lyophilized preparations of proteasome inhibitors
US11865180B2 (en) Levothyroxine formulations for oral use
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
JP6516831B2 (ja) シクロホスファミド液状濃縮物の製剤
EP2434886A1 (en) Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US20220047509A1 (en) Stabilized liquid formulation of levothyroxine
US20250205155A1 (en) Formulations comprising melphalan flufenamide and cyclodextrin
EP4055005A1 (en) Liquid melphalan composition
CN108601730A (zh) 万古霉素的制剂
CN111107837A (zh) 包含西普尼莫德的肠胃外制剂
EA052092B1 (ru) Препараты, содержащие мелфалана флуфенамид и циклодекстрин
US8716521B2 (en) Formulations of canfosfamide and their preparation
WO2019130228A1 (en) Stable liquid compositions of melphalan
CN120529922A (zh) 肽药物偶联物
JP2026016486A (ja) 安定なシクロデキストリン不含カルフィルゾミブ処方物
EP3747428A1 (en) Stable melphalan liquid injectable formulations
EA023081B1 (ru) Инъекционная лекарственная форма флупиртина
AU2011200939B1 (en) Formulations of Canfosfamide and their preparation
TW201302755A (zh) 含胺基酸穩定劑的替莫唑胺醫藥組成物及其製備方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000